PRESS RELEASE published on 03/28/2024 at 12:38, 7 months 24 days ago Biotest AG increased sales by 32% in the financial year 2023 Biotest AG reported 32% increase in sales for FY 2023, reaching revenue of €684.6 million. EBIT forecast achieved at €143 million. Key developments include Yimmugo marketing authorization in the US and successful Phase III study with fibrinogen Sales Increase EBIT Forecast Biotest AG Yimmugo Fibrinogen
PRESS RELEASE published on 02/29/2024 at 07:45, 8 months 21 days ago Biotest achieves EBIT forecast for 2023 Biotest achieves EBIT forecast for 2023, with EBIT of €143 million, meeting expectations. Sales reached €684 million, encompassing one-off effects. Final figures to be released on 28 March 2024 Financial Results Annual Report EBIT Forecast Biotest AG Preference Dividend
BRIEF published on 02/29/2024 at 07:45, 8 months 21 days ago Biotest announces performance in line with forecasts for 2023 Financial Results Biotest AG Turnover EBIT 2023 Preferential Dividend
BRIEF published on 02/29/2024 at 07:45, 8 months 21 days ago Biotest annonce une performance conforme aux prévisions pour 2023 Chiffre D'affaires Résultats Financiers Biotest AG EBIT 2023 Dividende Préférentiel
PRESS RELEASE published on 02/28/2024 at 10:00, 8 months 22 days ago Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care Prof Dr Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne, emphasizing vital contribution to patient care. Plasma donation in Germany crucial for medical supply Germany Patient Care Biotest AG Karl Lauterbach Plasma Donation
BRIEF published on 02/28/2024 at 10:00, 8 months 22 days ago Visit of Karl Lauterbach to the plasma donation center of Biotest AG in Cologne Germany Biotest AG Karl Lauterbach Plasma Donation Medical Care
BRIEF published on 02/28/2024 at 10:00, 8 months 22 days ago Visite de Karl Lauterbach au centre de donation de plasma de Biotest AG à Cologne Allemagne Biotest AG Don De Plasma Karl Lauterbach Soins Médicaux
PRESS RELEASE published on 02/14/2024 at 08:30, 9 months 7 days ago Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential Biotest AG Fibrinogen Concentrate Phase III Trial Study Results Medical Market Potential
PRESS RELEASE published on 11/28/2023 at 09:00, 11 months 23 days ago EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
PRESS RELEASE published on 11/02/2023 at 08:00, 1 year ago Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
Published on 11/22/2024 at 00:00, 4 hours 11 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 6 hours 6 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 6 hours 21 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 7 hours 56 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 8 hours 1 minute ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 19:01, 9 hours 10 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 9 hours 35 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 10 hours 13 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 10 hours 19 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 10 hours 19 minutes ago LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Published on 11/21/2024 at 06:58, 21 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 21 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 21 hours 13 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 8 hours ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 8 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting